Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
- Reyataz® (atazanavir sulfate)
- Sustiva® (efavirenz) — manufactured by Bristol-Myers Squibb for sale in the United States, Canada, and certain countries of the European Union
- Videx® (didanosine)
- Zerit® (stavudine)
- Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) — совместно с Gilead
Information about the drug products is obtained from public sources or from company representatives and is intended solely for informing community representatives about the options currently available or in development. This information can under no circumstances be intepreted as advertising. The mentioning of any drug products does not mean EECA CAB prioritizes those products or, on the contrary, does not recommend them.
HIV pipeline
- Nucleoside or nucleotide reverse transcriptase inhibitor
- BMS-986001, once-daily, phase II
- Entry and Fusion Inhibitor
- BMS-663068, phase II
Hepatitis C pipeline
- Inhibitors of NS5A
- daclatasvir (BMS-790052), once a day, phase III
- Protease inhibitors
- asunaprevir (BMS-650032), twice a day, phase III
Will be available soon.
